XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 69 Months Ended
Mar. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jul. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
USD ($)
performanceObligation
Dec. 31, 2018
USD ($)
performanceObligation
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 31, 2022
Collaboration And Other Agreements [Line Items]                          
Revenues   $ 10,397 $ 41,734   $ 48,029 $ 78,842              
Deferred revenue, current   18,584     18,584         $ 18,584   $ 9,988  
Deferred revenue, net of current portion   64,260     64,260         64,260   $ 59,480  
Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment               $ 150,000          
Potential commercial milestone payments under agreement               330,000 $ 330,000        
Potential development and regulatory milestone payments under agreement               435,000 435,000        
Development and regulatory milestones recognized $ 15,000                 115,000      
Collaborative agreement transaction price               $ 154,000 154,000        
Variable consideration recognized                 $ 4,000        
Number of performance obligations | performanceObligation               2 2        
I-Mab | I-Mab Biopharma Collaboration and License Agreement                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment             $ 15,000            
Revenues   0 3,800   0 4,500              
Development and regulatory milestones recognized         5,000                
Minimum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)               15.00%          
Maximum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)               24.00%          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Revenues     30,000   15,000 30,000   $ 150,000          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                          
Collaboration And Other Agreements [Line Items]                          
Revenues   200 100   1,700 600              
RevenuesFromCMOAgreementsMember | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment       $ 10,000                  
Annual Fixed Payments   14,400     14,400         14,400      
Revenues   4,500 $ 1,100   9,600 $ 5,100              
Deferred revenue   7,000     7,000         7,000      
Deferred revenue, current   6,400     6,400         6,400      
Deferred revenue, net of current portion   600     600         600      
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Annual Fixed Payments                     $ 19,500    
Additional Payments   $ 5,100     $ 5,100         $ 5,100      
Manufacturing Services | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Extension term       1 year                  
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                          
Collaboration And Other Agreements [Line Items]                          
Revenue, remaining performance obligation, expected timing of satisfaction                         3 years